NCT07114861 - The KN510713 Study in Combination With mFOLFIRINOX | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 22, 2025

Primary Completion Date

September 22, 2028

Study Completion Date

October 22, 2028

Conditions

Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Interventions

DRUG

Study drug: KN510 120mg/day + KN713 90mg/day, Combination Chemotherapy: mFOLFIRINOX

KN510 120mg/day + KN713 90mg/day: once daily in 14-day (2-week) cycles. mFOLFIRINOX: Treatment is repeated every 2 weeks

DRUG

Study drug: KN510 120mg/day + KN713 120mg/day, Combination Chemotherapy: mFOLFIRINOX

KN510 120mg/day + KN713 120mg/day: once daily in 14-day (2-week) cycles. mFOLFIRINOX: Treatment is repeated every 2 weeks

Trial Locations (1)

National Cancer Center, Goyang-si

All Listed Sponsors

lead

New Cancer Cure-Bio Co.,Ltd.

INDUSTRY